NervGen Pharma Corp. (NGEN)
NASDAQ (CM) 
Summary
NGEN Chart
NervGen Pharma Corp. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $3.77 | $1.68 | -$2.09 | -55.44% |
| PIL PFG Investments LLC PFG Investments LLC | 201,000 | $757,770 | $333,599.7 | -$424,170.3 | -55.98% |
 Kevin Bresler TD Waterhouse Canada Inc. | 23,800 | $89,726 | $38,794 | -$50,932 | -56.76% |
| SAM Smartleaf Asset Management LLC Smartleaf Asset Management LLC | 3,656 | $13,637 | $5,941 | -$7,696 | -56.43% |
 Cynthia Schlanger Ashton Thomas Private Wealth, LLC | 10,700 | $40,339 | $17,334 | -$23,005 | -57.03% |
NervGen Pharma Corp. (NGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NervGen Pharma Corp. ever had a stock split?
NervGen Pharma Corp. Profile
| Biotechnology Industry | Healthcare Sector | Adam H. Rogers CEO | NASDAQ (CM) Exchange | 64082X203 CUSIP |
| CA Country | 11 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
NervGen Pharma Corp. is a company dedicated to the discovery, development, and commercialization of innovative pharmaceutical treatments aimed at addressing medical conditions associated with nervous system damage. The company operates through its subsidiaries and focuses on offering novel solutions for challenging conditions like spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. Founded in 2017, NervGen Pharma Corp. has established a significant presence in the biopharmaceutical field, showcasing its commitment to advancing healthcare outcomes for patients worldwide. It is based in Vancouver, Canada, positioning itself in a vibrant hub for biotechnology research and development.
Products and Services
- NVG-291
NVG-291 is NervGen Pharma's lead product candidate, currently undergoing a phase 1 clinical trial. This promising therapeutic agent targets conditions such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The development of NVG-291 is based on its potential to address the underlying damage to the nervous system that contributes to these conditions, aiming to improve functional recovery and patient outcomes significantly.
- Licensing Agreement with Case Western Reserve University
NervGen Pharma Corp. has secured a licensing agreement with Case Western Reserve University, granting it the rights to research, develop, and commercialize a patented technology with potential therapeutic benefits for SCI and other nerve damage-associated conditions. This collaboration underscores NervGen's strategy to leverage academic partnerships to enrich its pipeline and hasten the development of groundbreaking treatments for nerve damage and associated diseases.
